Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 Shares

Inozyme Pharma, Inc. (NASDAQ:INZYGet Free Report) CEO Douglas A. Treco sold 7,523 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the transaction, the chief executive officer now directly owns 20,665 shares of the company’s stock, valued at $143,415.10. The sale was disclosed in a filing with the SEC, which is available at this link.

Inozyme Pharma Stock Up 3.5 %

Shares of INZY opened at $7.17 on Thursday. Inozyme Pharma, Inc. has a 1 year low of $2.69 and a 1 year high of $7.80. The company has a debt-to-equity ratio of 0.32, a current ratio of 13.36 and a quick ratio of 13.36. The stock has a 50 day simple moving average of $5.99 and a 200-day simple moving average of $4.58.

Inozyme Pharma (NASDAQ:INZYGet Free Report) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). As a group, equities research analysts expect that Inozyme Pharma, Inc. will post -1.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

INZY has been the subject of a number of recent research reports. Wedbush reissued an “outperform” rating and issued a $15.00 target price on shares of Inozyme Pharma in a report on Tuesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Inozyme Pharma in a report on Wednesday, March 13th.

Check Out Our Latest Stock Analysis on INZY

Institutional Investors Weigh In On Inozyme Pharma

A number of large investors have recently bought and sold shares of INZY. Citigroup Inc. grew its position in Inozyme Pharma by 241.6% during the 1st quarter. Citigroup Inc. now owns 12,517 shares of the company’s stock worth $51,000 after acquiring an additional 8,853 shares during the last quarter. BlackRock Inc. boosted its position in Inozyme Pharma by 4.9% in the 1st quarter. BlackRock Inc. now owns 878,400 shares of the company’s stock valued at $3,593,000 after buying an additional 41,402 shares during the last quarter. Renaissance Technologies LLC bought a new position in Inozyme Pharma in the 1st quarter valued at $49,000. PDT Partners LLC bought a new position in Inozyme Pharma in the 1st quarter valued at $42,000. Finally, Rock Springs Capital Management LP boosted its position in Inozyme Pharma by 37.4% in the 1st quarter. Rock Springs Capital Management LP now owns 1,193,195 shares of the company’s stock valued at $4,880,000 after buying an additional 324,729 shares during the last quarter. 88.30% of the stock is currently owned by institutional investors.

Inozyme Pharma Company Profile

(Get Free Report)

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.

Featured Articles

Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.